Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for Chronic Idiopathic Itch
NCT02909569Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in chronic idiopathic pruritus, sponsored by Washington University School of Medicine. Primary endpoint: Numerical Rating Scale Itch Score at 12 weeks. Planned start Aug 2018; status: withdrawn.
02
Drugs
itacitinib
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on NCT02909569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909569.